Sandy Srinivas
Publication Details
-
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Am J Clin Oncol. 2008; (5): 417-23
Despite the introduction of newer treatment approaches in metastatic renal cell carcinoma (mRCC), overall survival remains disappointing and further exploration of current chemotherapeutic agents for second or third-line treatment is imperative. We conducted a phase II trial to determine the efficacy and safety of the combination of thalidomide and capecitabine in mRCC.
Help
Trial Administration